{"transactions":[{"id":697013,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2026-08-04T20:11:11.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":0.63,"exercise_date":"2027-07-31","expiration_date":"2036-07-31","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-26-085192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390026085192/ownership.xml","form_type":"4"}},{"id":696748,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26537,"kind":"person","name":"Lucas Svetlana","position":1,"cik":"0001781292","reported_name":"Lucas Svetlana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2026-08-04T20:10:57.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":0.63,"exercise_date":"2027-07-31","expiration_date":"2036-07-31","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-26-085191","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781292/000121390026085191/ownership.xml","form_type":"4"}},{"id":697244,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26665,"kind":"person","name":"Crutcher Patrick J","position":1,"cik":"0001754540","reported_name":"Crutcher Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2026-08-04T20:10:44.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":0.63,"exercise_date":"2027-07-31","expiration_date":"2036-07-31","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-26-085190","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754540/000121390026085190/ownership.xml","form_type":"4"}},{"id":696987,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2026-08-04T20:10:32.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":0.63,"exercise_date":"2027-07-31","expiration_date":"2036-07-31","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-26-085189","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390026085189/ownership.xml","form_type":"4"}},{"id":698039,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26873,"kind":"person","name":"Shizuru Judith Anne","position":1,"cik":"0001883000","reported_name":"Shizuru Judith Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2026-08-04T20:10:19.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":0.63,"exercise_date":"2027-07-31","expiration_date":"2036-07-31","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-26-085188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883000/000121390026085188/ownership.xml","form_type":"4"}},{"id":704693,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":29152,"kind":"person","name":"Ros Matthew E","position":1,"cik":"0001461613","reported_name":"Ros Matthew E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Non-Voting Convertible Preferred Stock","published_at":"2026-07-22T23:10:49.000Z","date":"2026-07-20","kind":"purchase","planned":false,"acquired":true,"shares":881,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."}],"balance_after":881,"derivative":{"underlying":"Voting Common Stock","underlying_shares":53741},"source":{"system":"sec-edgar","filing":"0001213900-26-080525","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1461613/000121390026080525/ownership.xml","form_type":"4"}},{"id":705804,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26665,"kind":"person","name":"Crutcher Patrick J","position":1,"cik":"0001754540","reported_name":"Crutcher Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Voting Convertible Preferred Stock","published_at":"2026-07-21T00:38:57.000Z","date":"2026-07-20","kind":"purchase","planned":false,"acquired":true,"shares":888,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"shares","element":"transactionShares","label":"F3","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."}],"balance_after":888,"derivative":{"underlying":"Voting Common Stock","underlying_shares":888},"source":{"system":"sec-edgar","filing":"0001213900-26-079764","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754540/000121390026079764/ownership.xml","form_type":"4"}},{"id":705803,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26665,"kind":"person","name":"Crutcher Patrick J","position":1,"cik":"0001754540","reported_name":"Crutcher Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2026-07-21T00:38:57.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares shall vest as follows: 25% on the one-year anniversary of the date of grant and the remaining shares shall vest in equal monthly installments over the next 36 months until fully vested, subject to continuous service through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares shall vest as follows: 25% on the one-year anniversary of the date of grant and the remaining shares shall vest in equal monthly installments over the next 36 months until fully vested, subject to continuous service through each applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":0.774,"underlying":"Voting Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001213900-26-079764","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754540/000121390026079764/ownership.xml","form_type":"4"}},{"id":912282,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-10T16:00:23.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 6, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":500000,"derivative":{"exercise_price":1.35,"expiration_date":"2036-02-06","underlying":"Voting Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001213900-26-014244","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390026014244/ownership.xml","form_type":"4"}},{"id":952488,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T19:30:55.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":234000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":234000,"derivative":{"exercise_price":1.84,"expiration_date":"2036-01-02","underlying":"Voting Common Stock","underlying_shares":234000},"source":{"system":"sec-edgar","filing":"0001213900-26-001385","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390026001385/ownership.xml","form_type":"4"}},{"id":952030,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T19:30:34.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":90000,"derivative":{"exercise_price":1.84,"expiration_date":"2036-01-02","underlying":"Voting Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001213900-26-001383","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390026001383/ownership.xml","form_type":"4"}},{"id":950533,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70274,"kind":"person","name":"CROSS HERB","position":1,"cik":"0001230721","reported_name":"CROSS HERB","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T19:30:17.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":90000,"derivative":{"exercise_price":1.84,"expiration_date":"2036-01-02","underlying":"Voting Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001213900-26-001382","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230721/000121390026001382/ownership.xml","form_type":"4"}},{"id":1032914,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2025-09-24T20:01:57.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":41000,"ownership":{"direct":false,"nature":"By Wiggans Living Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant."}],"balance_after":41000,"derivative":{"exercise_price":2.92,"exercise_date":"2026-03-22","expiration_date":"2030-03-22","underlying":"Voting Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001213900-25-091105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390025091105/ownership.xml","form_type":"4"}},{"id":1032913,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2025-09-24T20:01:57.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":41000,"price":2.43,"value":99630.0,"ownership":{"direct":false,"nature":"By Wiggans Living Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001213900-25-091105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390025091105/ownership.xml","form_type":"4"}},{"id":1032764,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26537,"kind":"person","name":"Lucas Svetlana","position":1,"cik":"0001781292","reported_name":"Lucas Svetlana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2025-09-24T20:01:38.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant."}],"balance_after":20000,"derivative":{"exercise_price":2.92,"exercise_date":"2026-03-22","expiration_date":"2030-03-22","underlying":"Voting Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001213900-25-091104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781292/000121390025091104/ownership.xml","form_type":"4"}},{"id":1032763,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26537,"kind":"person","name":"Lucas Svetlana","position":1,"cik":"0001781292","reported_name":"Lucas Svetlana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2025-09-24T20:01:38.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":2.43,"value":48600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001213900-25-091104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781292/000121390025091104/ownership.xml","form_type":"4"}},{"id":1033492,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26873,"kind":"person","name":"Shizuru Judith Anne","position":1,"cik":"0001883000","reported_name":"Shizuru Judith Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2025-09-24T20:01:03.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":41000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant."}],"balance_after":41000,"derivative":{"exercise_price":2.92,"exercise_date":"2026-03-22","expiration_date":"2030-03-22","underlying":"Voting Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001213900-25-091096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883000/000121390025091096/ownership.xml","form_type":"4"}},{"id":1033491,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26873,"kind":"person","name":"Shizuru Judith Anne","position":1,"cik":"0001883000","reported_name":"Shizuru Judith Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2025-09-24T20:01:03.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":41000,"price":2.43,"value":99630.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant."}],"balance_after":156901,"source":{"system":"sec-edgar","filing":"0001213900-25-091096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883000/000121390025091096/ownership.xml","form_type":"4"}},{"id":1033313,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock Warrant (right to buy)","published_at":"2025-09-24T16:01:19.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":41000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant."}],"balance_after":41000,"derivative":{"exercise_price":2.92,"exercise_date":"2026-03-22","expiration_date":"2030-03-22","underlying":"Voting Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001213900-25-091099","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390025091099/ownership.xml","form_type":"4"}},{"id":1033312,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Voting Common Stock","published_at":"2025-09-24T16:01:19.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":41000,"price":2.43,"value":99630.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant."}],"balance_after":74118,"source":{"system":"sec-edgar","filing":"0001213900-25-091099","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390025091099/ownership.xml","form_type":"4"}},{"id":1092690,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:25:47.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061503","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000121390025061503/ownership.xml","form_type":"4"}},{"id":1092039,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:24:56.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061501","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390025061501/ownership.xml","form_type":"4"}},{"id":1093534,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26873,"kind":"person","name":"Shizuru Judith Anne","position":1,"cik":"0001883000","reported_name":"Shizuru Judith Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:24:09.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061500","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883000/000121390025061500/ownership.xml","form_type":"4"}},{"id":1091747,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:23:04.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061498","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000121390025061498/ownership.xml","form_type":"4"}},{"id":1091745,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":77681,"kind":"person","name":"Kapoor Vishal","position":1,"cik":"0001798946","reported_name":"Kapoor Vishal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:22:13.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061495","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025061495/ownership.xml","form_type":"4"}},{"id":1092067,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:21:18.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061493","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390025061493/ownership.xml","form_type":"4"}},{"id":1091761,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26537,"kind":"person","name":"Lucas Svetlana","position":1,"cik":"0001781292","reported_name":"Lucas Svetlana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:20:10.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061492","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781292/000121390025061492/ownership.xml","form_type":"4"}},{"id":1119093,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":78774,"kind":"person","name":"Tucker Edwin Jonathan","position":1,"cik":"0001792296","reported_name":"Tucker Edwin Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T10:23:17.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":90000,"derivative":{"exercise_price":6,"expiration_date":"2035-06-04","underlying":"Voting Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001213900-25-051722","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025051722/ownership.xml","form_type":"4"}},{"id":1120060,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T06:30:06.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":234000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":234000,"derivative":{"exercise_price":6,"expiration_date":"2035-06-04","underlying":"Voting Common Stock","underlying_shares":234000},"source":{"system":"sec-edgar","filing":"0001213900-25-051729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390025051729/ownership.xml","form_type":"4"}},{"id":1119932,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T06:27:57.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":90000,"derivative":{"exercise_price":6,"expiration_date":"2035-06-04","underlying":"Voting Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001213900-25-051726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390025051726/ownership.xml","form_type":"4"}},{"id":1119350,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70274,"kind":"person","name":"CROSS HERB","position":1,"cik":"0001230721","reported_name":"CROSS HERB","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T06:25:18.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":90000,"derivative":{"exercise_price":6,"expiration_date":"2035-06-04","underlying":"Voting Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001213900-25-051724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230721/000121390025051724/ownership.xml","form_type":"4"}},{"id":1263195,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":78774,"kind":"person","name":"Tucker Edwin Jonathan","position":1,"cik":"0001792296","reported_name":"Tucker Edwin Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-18T22:29:46.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 13, 2026, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":50000,"derivative":{"exercise_price":6.2,"expiration_date":"2035-02-13","underlying":"Voting Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-25-014948","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025014948/ownership.xml","form_type":"4"}},{"id":1264058,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-18T17:31:26.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 13, 2026, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":50000,"derivative":{"exercise_price":6.2,"expiration_date":"2035-02-13","underlying":"Voting Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-25-014951","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390025014951/ownership.xml","form_type":"4"}},{"id":1264486,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-18T17:30:52.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 13, 2026, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":130000,"derivative":{"exercise_price":6.2,"expiration_date":"2035-02-13","underlying":"Voting Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001213900-25-014950","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390025014950/ownership.xml","form_type":"4"}},{"id":1263449,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70274,"kind":"person","name":"CROSS HERB","position":1,"cik":"0001230721","reported_name":"CROSS HERB","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-18T17:30:21.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 13, 2026, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":50000,"derivative":{"exercise_price":6.2,"expiration_date":"2035-02-13","underlying":"Voting Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001213900-25-014949","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230721/000121390025014949/ownership.xml","form_type":"4"}},{"id":1334165,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-12T20:02:41.000Z","date":"2024-12-12","kind":"exercise","planned":true,"acquired":true,"shares":900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter."}],"balance_after":13772,"derivative":{"exercise_price":7.1,"expiration_date":"2030-05-31","underlying":"Voting Common Stock","underlying_shares":900},"source":{"system":"sec-edgar","filing":"0001213900-24-108551","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024108551/ownership.xml","form_type":"4"}},{"id":1334164,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Voting Common Stock","published_at":"2024-12-12T20:02:41.000Z","date":"2024-12-12","kind":"sale","planned":true,"acquired":false,"shares":900,"price":22.11,"value":19899.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."}],"balance_after":25009,"source":{"system":"sec-edgar","filing":"0001213900-24-108551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024108551/ownership.xml","form_type":"4"}},{"id":1334163,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Voting Common Stock","published_at":"2024-12-12T20:02:41.000Z","date":"2024-12-12","kind":"exercise","planned":true,"acquired":true,"shares":900,"price":7.1,"value":6390.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."}],"balance_after":25909,"source":{"system":"sec-edgar","filing":"0001213900-24-108551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024108551/ownership.xml","form_type":"4"}},{"id":1408814,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-12T17:19:07.000Z","date":"2024-09-12","kind":"exercise","planned":true,"acquired":true,"shares":900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter."}],"balance_after":14672,"derivative":{"exercise_price":7.1,"expiration_date":"2030-05-31","underlying":"Voting Common Stock","underlying_shares":900},"source":{"system":"sec-edgar","filing":"0001213900-24-078214","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024078214/ownership.xml","form_type":"4"}},{"id":1408813,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Voting Common Stock","published_at":"2024-09-12T17:19:07.000Z","date":"2024-09-12","kind":"sale","planned":true,"acquired":false,"shares":900,"price":21.2263,"value":19103.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.795 to $21.495, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":25009,"source":{"system":"sec-edgar","filing":"0001213900-24-078214","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024078214/ownership.xml","form_type":"4"}},{"id":1408812,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Voting Common Stock","published_at":"2024-09-12T17:19:07.000Z","date":"2024-09-12","kind":"exercise","planned":true,"acquired":true,"shares":900,"price":7.1,"value":6390.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."}],"balance_after":25909,"source":{"system":"sec-edgar","filing":"0001213900-24-078214","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024078214/ownership.xml","form_type":"4"}},{"id":1472708,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26537,"kind":"person","name":"Lucas Svetlana","position":1,"cik":"0001781292","reported_name":"Lucas Svetlana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-20T10:07:48.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on June 18, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":15000,"derivative":{"exercise_price":23.19,"expiration_date":"2034-06-18","underlying":"Voting Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001213900-24-053989","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781292/000121390024053989/ownership.xml","form_type":"4"}},{"id":1482284,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-12T21:40:02.000Z","date":"2024-06-12","kind":"exercise","planned":true,"acquired":true,"shares":900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter."}],"balance_after":15572,"derivative":{"exercise_price":7.1,"expiration_date":"2030-05-31","underlying":"Voting Common Stock","underlying_shares":900},"source":{"system":"sec-edgar","filing":"0001213900-24-052215","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024052215/ownership.xml","form_type":"4"}},{"id":1482283,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Voting Common Stock","published_at":"2024-06-12T21:40:02.000Z","date":"2024-06-12","kind":"sale","planned":true,"acquired":false,"shares":900,"price":24.155,"value":21739.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.975 to $24.555, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":25009,"source":{"system":"sec-edgar","filing":"0001213900-24-052215","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024052215/ownership.xml","form_type":"4"}},{"id":1482282,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Voting Common Stock","published_at":"2024-06-12T21:40:02.000Z","date":"2024-06-12","kind":"exercise","planned":true,"acquired":true,"shares":900,"price":7.1,"value":6390.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."}],"balance_after":25909,"source":{"system":"sec-edgar","filing":"0001213900-24-052215","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024052215/ownership.xml","form_type":"4"}},{"id":1482396,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Performance Restricted Stock Units","published_at":"2024-06-12T16:09:26.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents a grant of performance-based restricted stock units (\"PRSUs\"), with each PRSU representing a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"If, by June 10, 2026, the closing price of the Issuer's common stock on the Nasdaq Capital Market is at or above $35.00 per share (subject to adjustment for recapitalizations, stock splits and similar transactions) for thirty consecutive calendar days, all of the shares of the Issuer's common stock subject to the PRSUs shall vest in full on such thirtieth day, so long as the Reporting Person provides continuous services to the Issuer on and through the vesting date, inclusive."}],"balance_after":20000,"derivative":{"expiration_date":"2026-06-10","underlying":"Voting Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001213900-24-052087","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390024052087/ownership.xml","form_type":"4"}},{"id":1482395,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-12T16:09:26.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on June 10, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":10000,"derivative":{"exercise_price":23.95,"expiration_date":"2034-06-10","underlying":"Voting Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-24-052087","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390024052087/ownership.xml","form_type":"4"}},{"id":1484378,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":78774,"kind":"person","name":"Tucker Edwin Jonathan","position":1,"cik":"0001792296","reported_name":"Tucker Edwin Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Voting Common Stock","published_at":"2024-06-10T22:31:44.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":400,"price":4.1735,"value":1669.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":400,"source":{"system":"sec-edgar","filing":"0001213900-24-051417","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024051417/ownership.xml","form_type":"4"}},{"id":1484380,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T22:28:49.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051414","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000121390024051414/ownership.xml","form_type":"4"}},{"id":1485636,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26873,"kind":"person","name":"Shizuru Judith Anne","position":1,"cik":"0001883000","reported_name":"Shizuru Judith Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T22:25:56.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051411","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883000/000121390024051411/ownership.xml","form_type":"4"}},{"id":1484377,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":77681,"kind":"person","name":"Kapoor Vishal","position":1,"cik":"0001798946","reported_name":"Kapoor Vishal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T22:24:03.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051409","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024051409/ownership.xml","form_type":"4"}},{"id":1484656,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T22:20:25.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051405","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390024051405/ownership.xml","form_type":"4"}},{"id":1485163,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T22:17:19.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051401","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000121390024051401/ownership.xml","form_type":"4"}},{"id":1484616,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T22:15:36.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051398","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390024051398/ownership.xml","form_type":"4"}},{"id":1485171,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":90100,"kind":"person","name":"French Anna Louise","position":1,"cik":"0001871871","reported_name":"French Anna Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T18:30:25.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871871/000121390024051416/ownership.xml","form_type":"4"}},{"id":1581681,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-12T21:33:11.000Z","date":"2024-03-12","kind":"exercise","planned":false,"acquired":true,"shares":900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of the option and number of shares subject to the option were adjusted as a result of the Reverse Split, and numbers reported herein reflect the exercise price and number of shares subject to the option after the Reverse Split."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The exercise price of the option and number of shares subject to the option were adjusted as a result of the Reverse Split, and numbers reported herein reflect the exercise price and number of shares subject to the option after the Reverse Split."}],"balance_after":16472,"derivative":{"exercise_price":7.1,"expiration_date":"2030-05-31","underlying":"Voting Common Stock","underlying_shares":900},"source":{"system":"sec-edgar","filing":"0001213900-24-021961","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024021961/ownership.xml","form_type":"4"}},{"id":1581680,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Voting Common Stock","published_at":"2024-03-12T21:33:11.000Z","date":"2024-03-12","kind":"sale","planned":false,"acquired":false,"shares":900,"price":26.4358,"value":23792.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.79, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":25009,"source":{"system":"sec-edgar","filing":"0001213900-24-021961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024021961/ownership.xml","form_type":"4"}},{"id":1581679,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Voting Common Stock","published_at":"2024-03-12T21:33:11.000Z","date":"2024-03-12","kind":"exercise","planned":false,"acquired":true,"shares":900,"price":7.1,"value":6390.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective on January 4, 2024, the Issuer conducted a reverse stock split of its voting common stock at a ratio of 1-for-10 (the \"Reverse Split\"). The number of shares reported herein reflects the number of shares after the Reverse Split."}],"balance_after":25909,"source":{"system":"sec-edgar","filing":"0001213900-24-021961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024021961/ownership.xml","form_type":"4"}},{"id":1632401,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":78774,"kind":"person","name":"Tucker Edwin Jonathan","position":1,"cik":"0001792296","reported_name":"Tucker Edwin Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-21T00:22:06.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 15, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":45000,"derivative":{"exercise_price":17.95,"expiration_date":"2034-02-15","underlying":"Voting Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001213900-24-015457","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024015457/ownership.xml","form_type":"4"}},{"id":1634465,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-20T19:33:18.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 15, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":100000,"derivative":{"exercise_price":17.95,"expiration_date":"2034-02-15","underlying":"Voting Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-24-015465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390024015465/ownership.xml","form_type":"4"}},{"id":1634275,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-20T19:31:13.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 15, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":40000,"derivative":{"exercise_price":17.95,"expiration_date":"2034-02-15","underlying":"Voting Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-24-015462","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390024015462/ownership.xml","form_type":"4"}},{"id":1633066,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70274,"kind":"person","name":"CROSS HERB","position":1,"cik":"0001230721","reported_name":"CROSS HERB","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-20T19:27:04.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 15, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":40000,"derivative":{"exercise_price":17.95,"expiration_date":"2034-02-15","underlying":"Voting Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-24-015459","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230721/000121390024015459/ownership.xml","form_type":"4"}},{"id":1650521,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94435,"kind":"organization","name":"Abingworth Bioventures VII LP","position":10,"cik":"0001688313","reported_name":"Abingworth Bioventures VII LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2024-02-12T18:23:53.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":190000,"price":12.95,"value":2460500.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The amount of Voting Common Stock reported herein reflects a 1-for-10 reverse stock split effected by the Issuer on January 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by Abingworth Bioventures VII LP (\"ABV VII\"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any."}],"balance_after":1066189,"source":{"system":"sec-edgar","filing":"0000950170-24-014017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000095017024014017/ownership.xml","form_type":"4"}},{"id":1651937,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":87532,"kind":"organization","name":"Velan Capital Investment Management LP","position":1,"cik":"0001848809","reported_name":"Velan Capital Investment Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87533,"kind":"organization","name":"Velan Capital Master Fund LP","position":2,"cik":"0001964356","reported_name":"Velan Capital Master Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote 1"}},{"id":94457,"kind":"organization","name":"Avego Healthcare Capital, L.P.","position":3,"cik":"0001822834","reported_name":"Avego Healthcare Capital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote 1"}},{"id":87535,"kind":"organization","name":"Velan Capital Holdings LLC","position":4,"cik":"0001964353","reported_name":"Velan Capital Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote 1"}},{"id":94458,"kind":"organization","name":"Avego Healthcare Capital Holdings, LLC","position":5,"cik":"0001964446","reported_name":"Avego Healthcare Capital Holdings, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote 1"}},{"id":94459,"kind":"organization","name":"Avego Management LLC","position":6,"cik":"0001886177","reported_name":"Avego Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote 1"}},{"id":87536,"kind":"organization","name":"Velan Capital Management LLC","position":7,"cik":"0001964355","reported_name":"Velan Capital Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87537,"kind":"person","name":"VENKATARAMAN BALAJI","position":8,"cik":"0001114916","reported_name":"VENKATARAMAN BALAJI","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":68065,"kind":"person","name":"Morgan Adam","position":9,"cik":"0001964335","reported_name":"Morgan Adam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2024-02-09T20:40:05.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":350000,"price":12.95,"value":4532500.0,"ownership":{"direct":false,"nature":"By Velan Capital Master Fund LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Velan Capital Master Fund LP (\"Velan Master\"), Avego Healthcare Capital, L.P. (\"Avego Fund\"), Velan Capital Holdings LLC (\"Velan GP\"), Avego Healthcare Capital Holdings, LLC (\"Avego GP\"), Avego Management, LLC (\"Avego Management\"), Velan Capital Investment Management LP (\"Velan Capital\"), Velan Capital Management LLC (\"Velan IM GP\"), Balaji Venkataraman and Adam Morgan (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that no longer collectively beneficially owns more than 10% of the Issuer's outstanding shares. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects a 1-for-10 reverse stock split of the Issuer's common stock, effected on January 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities owned directly by Velan Master. As the general partner of Velan Master, Velan GP may be deemed to beneficially own the securities owned directly by Velan Master. As the investment manager of Velan Master, Velan Capital may be deemed to beneficially own the securities owned directly by Velan Master. As the general partner of Velan Capital, Velan IM GP may be deemed to beneficially own the securities owned directly by Velan Master. As the managing members of Velan GP and Velan IM GP, Messrs. Venkataraman and Morgan may be deemed to beneficially own the securities owned directly by Velan Master."}],"balance_after":1188500,"source":{"system":"sec-edgar","filing":"0000921895-24-000337","document":"form412927020_02092024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114916/000092189524000337/form412927020_02092024.xml","form_type":"4"}},{"id":1726636,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-11-30T21:05:16.000Z","date":"2023-11-28","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.6486,"value":6486.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6311 to $0.669, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001213900-23-091458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023091458/ownership.xml","form_type":"4"}},{"id":1730969,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-11-22T21:06:03.000Z","date":"2023-11-21","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.6383,"value":6383.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63 to $0.65, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001213900-23-089579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023089579/ownership.xml","form_type":"4"}},{"id":1734314,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-11-21T01:14:16.000Z","date":"2023-11-20","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.6309,"value":6309.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.616 to $0.64, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001213900-23-088896","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023088896/ownership.xml","form_type":"4"}},{"id":1734313,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-11-21T01:14:16.000Z","date":"2023-11-17","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.5966,"value":5966.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5889 to $0.60, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001213900-23-088896","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023088896/ownership.xml","form_type":"4"}},{"id":1734312,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-11-21T01:14:16.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.5965,"value":5965.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001213900-23-088896","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023088896/ownership.xml","form_type":"4"}},{"id":1751141,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-11-02T22:00:55.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on November 1, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":110000,"derivative":{"exercise_price":0.69,"expiration_date":"2033-11-01","underlying":"Voting Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001213900-23-082883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023082883/ownership.xml","form_type":"4"}},{"id":1760470,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-10-13T22:56:56.000Z","date":"2023-10-13","kind":"sale","planned":true,"acquired":false,"shares":7965,"price":0.8508,"value":6776.622,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a trading plan intended to comply with Rule 10b5-1(c) and adopted by the Reporting Person on June 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.84 to $0.8717, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":53521,"source":{"system":"sec-edgar","filing":"0001013762-23-003901","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000101376223003901/ownership.xml","form_type":"4"}},{"id":1760664,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Voting Common Stock","published_at":"2023-10-13T18:58:59.000Z","date":"2023-10-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":37126,"price":0.85,"value":31557.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units."}],"balance_after":250097,"source":{"system":"sec-edgar","filing":"0001013762-23-003903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000101376223003903/ownership.xml","form_type":"4"}},{"id":1760677,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO & Director"}}],"security":"Voting Common Stock","published_at":"2023-10-13T18:57:41.000Z","date":"2023-10-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":87531,"price":0.85,"value":74401.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units."}],"balance_after":331188,"source":{"system":"sec-edgar","filing":"0001013762-23-003902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000101376223003902/ownership.xml","form_type":"4"}},{"id":1773169,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70274,"kind":"person","name":"CROSS HERB","position":1,"cik":"0001230721","reported_name":"CROSS HERB","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:16:09.000Z","date":"2023-09-22","kind":"grant","planned":false,"acquired":true,"shares":550000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on September 22, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":550000,"derivative":{"exercise_price":0.78,"expiration_date":"2033-09-22","underlying":"Voting Common Stock","underlying_shares":550000},"source":{"system":"sec-edgar","filing":"0001213900-23-079569","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230721/000121390023079569/ownership.xml","form_type":"4"}},{"id":1849893,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T01:48:28.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":94000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on June 20, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":94000,"derivative":{"exercise_price":1.35,"expiration_date":"2033-06-20","underlying":"Voting Common Stock","underlying_shares":94000},"source":{"system":"sec-edgar","filing":"0001213900-23-050220","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000121390023050220/ownership.xml","form_type":"4"}},{"id":1856816,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":78774,"kind":"person","name":"Tucker Edwin Jonathan","position":1,"cik":"0001792296","reported_name":"Tucker Edwin Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-14T00:45:25.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on June 12, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":400000,"derivative":{"exercise_price":1.62,"expiration_date":"2033-06-12","underlying":"Voting Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001213900-23-048681","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023048681/ownership.xml","form_type":"4"}},{"id":1857453,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-13T20:54:21.000Z","date":"2023-06-13","kind":"exercise","planned":true,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares have vested and shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":173713,"derivative":{"exercise_price":0.71,"expiration_date":"2030-05-31","underlying":"Voting Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001213900-23-048683","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390023048683/ownership.xml","form_type":"4"}},{"id":1857452,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Voting Common Stock","published_at":"2023-06-13T20:54:21.000Z","date":"2023-06-13","kind":"sale","planned":true,"acquired":false,"shares":9000,"price":1.6572,"value":14914.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.69, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":287223,"source":{"system":"sec-edgar","filing":"0001213900-23-048683","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390023048683/ownership.xml","form_type":"4"}},{"id":1857451,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Voting Common Stock","published_at":"2023-06-13T20:54:21.000Z","date":"2023-06-13","kind":"exercise","planned":true,"acquired":true,"shares":9000,"price":0.71,"value":6390.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."}],"balance_after":296223,"source":{"system":"sec-edgar","filing":"0001213900-23-048683","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390023048683/ownership.xml","form_type":"4"}},{"id":1861675,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":77681,"kind":"person","name":"Kapoor Vishal","position":1,"cik":"0001798946","reported_name":"Kapoor Vishal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:44:45.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":1.6,"exercise_date":"2024-06-07","expiration_date":"2033-06-07","underlying":"Voting Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-23-047574","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023047574/ownership.xml","form_type":"4"}},{"id":1861698,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":18148,"kind":"person","name":"Klein Lawrence Otto","position":1,"cik":"0001762583","reported_name":"Klein Lawrence Otto","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:44:16.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":1.6,"exercise_date":"2024-06-07","expiration_date":"2033-06-07","underlying":"Voting Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-23-047573","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762583/000121390023047573/ownership.xml","form_type":"4"}},{"id":1861948,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:43:52.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":1.6,"exercise_date":"2024-06-07","expiration_date":"2033-06-07","underlying":"Voting Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-23-047571","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390023047571/ownership.xml","form_type":"4"}},{"id":1863038,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26873,"kind":"person","name":"Shizuru Judith Anne","position":1,"cik":"0001883000","reported_name":"Shizuru Judith Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:43:24.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":1.6,"exercise_date":"2024-06-07","expiration_date":"2033-06-07","underlying":"Voting Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-23-047570","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883000/000121390023047570/ownership.xml","form_type":"4"}},{"id":1861681,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:42:54.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":1.6,"exercise_date":"2024-06-07","expiration_date":"2033-06-07","underlying":"Voting Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-23-047569","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000121390023047569/ownership.xml","form_type":"4"}},{"id":1861798,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:42:24.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":1.6,"exercise_date":"2024-06-07","expiration_date":"2033-06-07","underlying":"Voting Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-23-047568","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390023047568/ownership.xml","form_type":"4"}},{"id":1862711,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":90100,"kind":"person","name":"French Anna Louise","position":1,"cik":"0001871871","reported_name":"French Anna Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T18:41:56.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":1.6,"exercise_date":"2024-06-07","expiration_date":"2033-06-07","underlying":"Voting Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-23-047567","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871871/000121390023047567/ownership.xml","form_type":"4"}},{"id":1919443,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-04-14T20:19:06.000Z","date":"2023-04-13","kind":"sale","planned":false,"acquired":false,"shares":9075,"price":1.4903,"value":13524.4725,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold by the Reporting Person solely in order to satisfy certain tax obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units."}],"balance_after":21175,"source":{"system":"sec-edgar","filing":"0001213900-23-029900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390023029900/ownership.xml","form_type":"4"}},{"id":1919372,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":23629,"kind":"person","name":"Lis William","position":1,"cik":"0001574558","reported_name":"Lis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-04-14T20:14:22.000Z","date":"2023-04-13","kind":"sale","planned":false,"acquired":false,"shares":8500,"price":1.44,"value":12240.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold by the Reporting Person solely in order to satisfy certain tax obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units."}],"balance_after":61486,"source":{"system":"sec-edgar","filing":"0001213900-23-029888","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574558/000121390023029888/ownership.xml","form_type":"4"}},{"id":1919711,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":90100,"kind":"person","name":"French Anna Louise","position":1,"cik":"0001871871","reported_name":"French Anna Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-04-14T16:19:42.000Z","date":"2023-04-14","kind":"sale","planned":false,"acquired":false,"shares":7000,"price":1.48,"value":10360.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold by the Reporting Person solely in order to satisfy certain tax obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units."}],"balance_after":23750,"source":{"system":"sec-edgar","filing":"0001213900-23-029901","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871871/000121390023029901/ownership.xml","form_type":"4"}},{"id":1919736,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Voting Common Stock","published_at":"2023-04-14T16:17:37.000Z","date":"2023-04-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":87531,"price":1.46,"value":127795.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units."}],"balance_after":418719,"source":{"system":"sec-edgar","filing":"0001213900-23-029896","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390023029896/ownership.xml","form_type":"4"}},{"id":1919720,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Voting Common Stock","published_at":"2023-04-14T16:16:34.000Z","date":"2023-04-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":37126,"price":1.46,"value":54203.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units."}],"balance_after":287223,"source":{"system":"sec-edgar","filing":"0001213900-23-029893","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390023029893/ownership.xml","form_type":"4"}},{"id":1921675,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":114538,"kind":"organization","name":"Qiming U.S. Healthcare Fund II, L.P.","position":1,"cik":"0001765710","reported_name":"Qiming U.S. Healthcare Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":114539,"kind":"organization","name":"Qiming U.S. Healthcare GP II, LLC","position":2,"cik":"0001868862","reported_name":"Qiming U.S. Healthcare GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73857,"kind":"person","name":"MCDADE MARK","position":3,"cik":"0001242126","reported_name":"MCDADE MARK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92115,"kind":"person","name":"RIESCHEL GARY E","position":4,"cik":"0001248153","reported_name":"RIESCHEL GARY E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2023-04-11T19:55:00.000Z","date":"2023-01-27","kind":"purchase","planned":false,"acquired":true,"shares":2666666,"price":1.5,"value":3999999.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. (\"Qiming\"). The general partner of Qiming is Qiming U.S. Healthcare GP II, LLC (\"Qiming GP\"). Gary Rieschel and Mark McDade are the managing partners of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. Each of Qiming GP and Messrs. Rieschel and McDade disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":8519648,"source":{"system":"sec-edgar","filing":"0001209191-23-024058","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1248153/000120919123024058/doc4.xml","form_type":"4"}},{"id":1944783,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":67062,"kind":"person","name":"Mahal Jeetinder Singh","position":1,"cik":"0001882877","reported_name":"Mahal Jeetinder Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-20T18:00:57.000Z","date":"2023-03-17","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on March 3, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":350000,"derivative":{"exercise_price":1.87,"expiration_date":"2033-03-17","underlying":"Voting Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001213900-23-021494","document":"marketforms-60959.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882877/000121390023021494/marketforms-60959.xml","form_type":"4"}},{"id":1944861,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-20T17:59:47.000Z","date":"2023-03-17","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on March 3, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":500000,"derivative":{"exercise_price":1.87,"expiration_date":"2033-03-17","underlying":"Voting Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001213900-23-021493","document":"marketforms-60958.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390023021493/marketforms-60958.xml","form_type":"4"}},{"id":2006293,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":77681,"kind":"person","name":"Kapoor Vishal","position":1,"cik":"0001798946","reported_name":"Kapoor Vishal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-17T13:30:07.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":109383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares subject to the option shall vest on February 16, 2024, and 1/3rd of the shares subject to the option shall vest on each anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":109383,"derivative":{"exercise_price":1.83,"expiration_date":"2033-02-16","underlying":"Voting Common stock","underlying_shares":109383},"source":{"system":"sec-edgar","filing":"0001213900-23-012598","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023012598/ownership.xml","form_type":"4"}},{"id":2033548,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":70393,"kind":"person","name":"MARTELL RON","position":1,"cik":"0001177079","reported_name":"MARTELL RON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO & Director"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-03T16:13:55.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":1093831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 2, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":1093831,"derivative":{"exercise_price":1.78,"expiration_date":"2033-02-02","underlying":"Voting Common Stock","underlying_shares":1093831},"source":{"system":"sec-edgar","filing":"0001213900-23-007992","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177079/000121390023007992/ownership.xml","form_type":"4"}},{"id":2040902,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":3,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":4,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":5,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":6,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":7,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":8,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":9,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2023-01-31T17:24:21.000Z","date":"2023-01-27","kind":"purchase","acquired":true,"shares":3133333,"price":1.5,"value":4699999.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures VII LP (\"ABV VII\"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any."}],"balance_after":8761891,"source":{"system":"sec-edgar","filing":"0000899243-23-003059","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323003059/doc4.xml","form_type":"4"}},{"id":2045639,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2023-01-26T17:49:09.000Z","date":"2023-01-25","kind":"sale","acquired":false,"shares":75000,"price":1.89,"value":141750.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held by Roche Finance Ltd (\"Roche Finance\"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd (\"Roche Holding\"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":4549606,"source":{"system":"sec-edgar","filing":"0001104659-23-007094","document":"tm234575-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/889131/000110465923007094/tm234575-1_4seq1.xml","form_type":"4"}},{"id":2137474,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":18148,"kind":"person","name":"Klein Lawrence Otto","position":1,"cik":"0001762583","reported_name":"Klein Lawrence Otto","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2022-10-14T00:07:16.000Z","date":"2022-10-12","kind":"grant","acquired":true,"shares":24500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":24500,"source":{"system":"sec-edgar","filing":"0001213900-22-063947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762583/000121390022063947/ownership.xml","form_type":"4"}},{"id":2137558,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2022-10-14T00:05:32.000Z","date":"2022-10-12","kind":"grant","acquired":true,"shares":30250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are represented by restricted stock units (the \"RSU Award\"), 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":30250,"source":{"system":"sec-edgar","filing":"0001213900-22-063945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390022063945/ownership.xml","form_type":"4"}}],"next_cursor":"2022-10-14T00:05:32.000000Z,2137558"}